Programmed death protein‐ligand 1 (PD‐L1) inhibitors demonstrate significant antitumor efficacy by modulating T‐cell activity and inhibiting the PD‐1/PD‐L1 pathway, thus enhancing immune responses. Despite their robust effects, systemic administration of these inhibitors is linked to severe immune toxicity. To address this issue, we engineered a strain, REP, which releases PD‐L1 nanoantibodies (PD‐L1nb) to treat breast cancer and attenuate immunotherapy‐related side effects. REP selectively targets tumors and periodically releases PD‐L1nb within tumors via a quorum‐sensing lysis system. Administration of 108 colony‐forming units (CFU) of REP led to a substantial 52% reduction in tumor growth, achieved through the sustained release of PD‐L1nb. Importantly, there were no detectable lesions in other organs, with the exception of mild intestinal damage. Further, we explored the potential of a combined treatment using Lactobacillus reuteri (LR) and REP to alleviate intestinal inflammation. LR modulates the expression of inflammatory markers IL‐1β, IL‐6, and IL‐10 through the JNK pathway, reducing intestinal inflammation without compromising REP's antitumor efficacy. Consequently, we formulated a dual strategy employing an engineered strain and probiotics to reduce the adverse effects of immunotherapy in cancer treatment.